Global Human Papillomavirus (HPV) Vaccine Market Insights Forecasts to 2033

• The Global Human Papillomavirus (HPV) Vaccine Market Size was valued at USD 4.52 Billion in 2023.
• The Market is Growing at a CAGR of 9.14% from 2023 to 2033.
• The Worldwide Human Papillomavirus (HPV) Vaccine Market Size is expected to reach USD 10.84 Billion by 2033.
• North America is expected to Grow the fastest during the forecast period.

The Global Human Papillomavirus (HPV) Vaccine Market Size is expected to reach USD 10.84 Billion by 2033, at a CAGR of 9.14% during the forecast period 2023 to 2033.

The HPV vaccine is a series of shots designed to protect from HPV (human papillomavirus) infection. Commonly transmitted through skin-to-skin contact, HPV is a sexually transmitted infection (STI). The 40 or so HPV strains that can spread through intercourse are known to exist. 80% of people who are sexually active will at some points have had HPV infection due to its widespread prevalence. Usually, immune systems in good health are able to combat viruses. HPV vaccination prevents HPV infections, which can lead to cancer or genital warts. The vaccine is not a treatment. Rather, it is a means of preventing infections. The vaccination cannot treat an infection caused by a specific strain of HPV if you have already been exposed to it. They consist of both low-risk and high-risk varieties. HPV strains with a high risk of cancer can advance. Low-risk varieties can result in bothersome conditions like genital warts, but they don't raise risk of cancer. According to the WHO report, as of 2023, there are 6 HPV vaccines available worldwide. All have been demonstrated to be safe and effective in preventing HPV infection and cervical cancer. They offer protection against the high-risk HPV types 16 and 18, which are responsible for the majority of cervical cancers.
All girls between the ages of 9 and 14 should receive HPV vaccinations as a priority, before they start engaging in sexual activity.

Report Coverage

This research report categorizes the market for the global human papillomavirus (HPV) vaccine market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global human papillomavirus (HPV) vaccine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global human papillomavirus (HPV) vaccine market.

Driving Factors

The demand for HPV vaccinations is rising due to the increased prevalence of diseases linked to HPV, and this is anticipated to be the main factor driving the global market opportunity for human papillomavirus vaccines over the forecast period. Only three types of vaccines quadruvalent, quadrivalent, and nonavalent are available on the market. Seventy percent of cervical cancer cases are cured because of virus types 16 and 18, which can be avoided with great success with all three vaccines. Furthermore, the efficacy and protection provided by HPV vaccines to reduce the negative effects associated with such infections is one of the market's most important and significant drivers. Global vaccination policies and attitudes have been seen to shift in recent years as manufacturers have created innovative vaccines. This may have improved the acceptance and uptake of HPV vaccinations. Clinical trials have demonstrated the effectiveness and safety of both bivalent and polyvalent vaccines in preventing HPV infections and cancer.

Restraining Factors        

Although HPV vaccines are in high demand due to their effectiveness in lowering infection rates, manufacturers' limited product offerings are expected to hamper market growth. Since the vaccine's delayed development, there will be a limited number of products released into the market.

Market Segmentation

By Type Insights

The polyvalent segment dominates the market with the largest revenue share over the forecast period.

On the basis of type, the global human papillomavirus (HPV) vaccine market is segmented into bivalent, and polyvalent. Among these, the polyvalent segment is dominating the market with the largest revenue share over the forecast period. In the global vaccine market, Merck's Gardasil/Gardasil 9 holds a dominant position due to its polyvalent nature. The quadrivalent vaccine Gardasil protects against strains of HPV 6, 11, 16, and 18. The vaccination aids in the defence against HPV infections and cancer. The nonavalent vaccine Gardasil 9 offers protection against nine high-risk HPV strains. Due to the fact that these two products offer protection against multiple strains of HPV, they are highly sought after and have higher global sales. The growth in sales of Gardasil/Gardasil 9 was primarily driven by increased demand in the European market and increased sales in the Asia Pacific region, especially in China.

By Disease Indication Insights

The cervical cancer segment is witnessing significant CAGR growth over the forecast period.

On the basis of disease indication, the global human papillomavirus (HPV) vaccine market is segmented into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Among these, the cervical cancer segment is witnessing significant growth over the forecast period. It is also expected to be the fastest-growing segment over the forecast period. This dominance is ascribed to the increased global sales of HPV-type vaccines, which are primarily used to prevent cervical cancer. Patients with cervical cancer have been found to carry high-risk strains of HPV16 and 18, which means that immunization against these strains is necessary. According to the World Health Organization (WHO), HPV infections are the root cause of 90% of anal cancers and 100% of cervical cancers.

By End User Insights

The public & private alliance segment is expected to hold the largest share of the global human papillomavirus (HPV) vaccine market during the forecast period.

Based on the end user, the global human papillomavirus (HPV) vaccine market is classified into public & private alliances, government entities, physicians, and others. Among these, the public & private alliance segment is expected to hold the largest share of the human papillomavirus (HPV) vaccine market during the forecast period. Public and private organizations work together in the majority of nations to treat human papillomavirus infections. In the estimated period, more initiatives of this nature are expected to propel the sub-segment market.

Regional Insights

Asia Pacific dominates the market with the largest market share over the forecast period.

Asia Pacific is dominating the market with the largest market share over the forecast period. Raising cases of cervical cancer and an increase in sexually transmitted diseases among the population are expected to be the primary driving forces for the market during the forecast period. Additionally, it is anticipated that during the forecast period, more investment opportunities will become available for the regional market due to a rise in major companies' investments in the establishment of vaccine manufacturing units throughout the region. Furthermore, the increased research and development to launch innovative vaccines is expected to boost market growth. For example, the Serum Institute of India (SII) and the Department of Biotechnology (DBT) developed the quadrivalent human papillomavirus vaccine (QHPV), which the Indian government introduced in September 2022 to prevent cervical cancer in India.

North America is expected to grow the fastest during the forecast period. In 2023, 13,960 new cases of cervical cancer are expected to be diagnosed in the United States, according to the American Cancer Society's (ACS) 2023 report. This is attributed to improved healthcare infrastructure and an increase in the prevalence of cervical cancer and other HPV-related cancers in the population.
Nine,440 new cases of anal cancer were diagnosed in the United States in 2022, according to a report released by the American Cancer Society. Furthermore, 1,450 Canadian women received a cervical cancer diagnosis in 2022, according to the Canadian Cancer Society.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global human papillomavirus (HPV) vaccine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Market Players

• GlaxoSmithKline plc.
• Novartis AG
• Inovio pharmaceuticals
• AstraZeneca
• Merck & Co., Inc 
• Bharat Biotech
• INOVIO Pharmaceuticals
• Walvax Biotechnology Co., Ltd
• Serum Institute of India Pvt. Ltd.
• Wantai BioPharm
•    Others

Key Market Developments

• On February 2023, A company representative stated that Serum Institute of India (SII), situated in Pune, intends to increase the yearly production capacity of the quadrivalent human papillomavirus (HPV) vaccines to approximately 70 million doses, commencing this year.
• In March 2023, Health Canada has approved an expanded indication of GARDASIL®9 in individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58 as well as the following diseases associated with the HPV types included in the vaccine.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2032. Spherical Insights has segmented the global Human Papillomavirus (HPV) Vaccine market based on the below-mentioned segments:

Human Papillomavirus (HPV) Vaccine Market, Type Analysis

• Bivalent
• Polyvalent

Human Papillomavirus (HPV) Vaccine Market, Disease Indication Analysis

• Cervical Cancer
• Anal Cancer
• Vulvar & Vaginal Cance
• Penile Cancer
• Oropharyngeal Cancer
• Others

Human Papillomavirus (HPV) Vaccine Market, End User Analysis

• Public & Private Alliances
• Government Entities
• Physicians
• Others

Human Papillomavirus (HPV) Vaccine Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa